Polymeric micelle as a nanocarrier for delivery of therapeutic agents: A comprehensive review

Roshani D. Agrawal*, Amol A. Tatode, Nilesh R. Rarokar, Milind J. Umekar
Department of Pharmaceutics, Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur (M.S.) India

ABSTRACT

For selective and effective drug delivery of therapeutic agent nanocarriers are the most effective agents. Micelles are an aggregate of surfactant molecules that dispersed in a liquid colloid. Micelles have a variety of shapes such as spheres, rods, vesicles, tubules, and lamellae. The shape and size of a micelle are a function of the molecular geometry of its surfactant molecules and solution conditions such as surfactant concentration, temperature, pH, and ionic strength. Poly Ethylene Glycol (PEG) is the most commonly used hydrophilic segment of micelles for drug delivery. Besides PEG, other polymers including poly (N-vinyl pyrrolidone) (PVP) and poly (N-isopropyl acrylamide) (pNIPAM) have also been used as hydrophilic portion of micelles. In this review we all discuss about the polymeric micelles (PMs) as a nanocarriers for delivery of therapeutic agents.

Keywords: Polymeric Micelles, Colloids, Nanocarriers, Drug Delivery, Poly Ethylene Glycol(PEG)

1. Introduction

A micelle is a colloid formed by a surfactant in equilibrium with the molecules or with the ions that contribute at micelle formation. In the past decades, nanocarriers have emerged as an attractive research field in cancer therapy, including liposomes, micelles and nanoparticles made of various materials. Polymeric micelles (PMs) are extensively studied carriers for the delivery of poorly water-soluble drugs [1].

Based on the type of intermolecular forces driving the micelle formation, block copolymer micelles can be divided into several categories including hydrophobically assembled amphiphilic micelles, polymer-complex micelles, and micelles stemming from metal complexation [2]. The hydrophobically assembled micelles usually consist of amphiphilic macromolecules that have distinct hydrophobic and hydrophilic domains, and the commonly used block segments of copolymers have been summarized [3]. Upon exposure to aqueous medium, the amphiphilic molecules are spontaneously self-assembled into supramolecular core/shell structures and water-insoluble drugs can be loaded into the hydrophobic cores [4, 5].

Micelles have demonstrated a variety of shapes such as spheres, rods, vesicles, tubules, and lamellae depending on the relative length of hydrophobic/hydrophilic blocks as well as solvent environment [6-8]. Morphology of micelles has significant impact on the pharmacokinetic properties of micelles. For example, worm-like micelles have shown ten times longer circulation time compared with the spherical counterpart made of similar material [9]. The most commonly used hydrophobic segment of micelles for drug delivery is poly (ethylene glycol) (PEG), with a molecular weight of 2-15 kDa. PEG is highly water-soluble, non-toxic and neutrally charged. PEG forms a hydrophilic corona on the surface of micelles which minimizes the nonspecific interaction with blood components and prolongs the circulation time. Besides PEG, other polymers including poly(N-vinyl pyrrolidone) (PVP) [10] and poly(N-isopropyl acrylamide) (pNIPAM) [11] have also been used as hydrophilic portion of micelles.
2. Formation of Polymeric micelles

PMs are self-assembled core-shell nanostructures formed in an aqueous solution consisting of amphiphilic block copolymers [12-14]. Formation of micelles in aqueous solution occurs when the concentration of the block copolymer increases above a certain concentration named the critical aggregation concentration (CAC) or critical micelle concentration (CMC). At the CAC or CMC, hydrophobic segments of block copolymers start to associate to minimize the contact with water molecules, leading to the formation of a vesicular or core-shell micellar structure.

Theoretically, the formation of micelles is driven by decrease of free energy. The removal of hydrophobic fragments from the aqueous environment and the reestablishing of hydrogen bond network in water decrease free energy of the system and finally form the micelles. The typical methods used for encapsulation of poorly water-soluble drugs are dialysis method, oil-in-water emulsion solvent evaporation method, and solid dispersion method [15, 16]. Other methods used are direct dissolution [17, 18], complexation [19], chemical conjugation [20], and various solvent evaporation procedures [21].

3. pH sensitive PMs

The potential disadvantage of normal PMs can be solved by application of additional stimuli that cause micelle destabilization in a specially controlled manner thus increasing the selectivity and efficiency of drug delivery to target sites. External factors such as heat [22, 23], light [24], and sound (ultrasound) [25,26] have already been studied by many researchers. However, these external stimuli may only activate the carriers that are situated closely underneath the skin but not those deeply distributed in the body. The intracellular signals also play an important role in regulating drug release which causes a great deal of interests, and here we focus our attention on pH-responsive systems.

4. Mucoadhesive PMs

Nanocarriers for oral administration should adhere to mucous and cross the mucus layer. Drugs delivered to mucosal surfaces are usually efficiently removed by mucus clearance mechanisms [27]. The luminal surface of mucosal tissues is protected by a highly viscoelastic layer [28], and the protective coatings rapidly remove foreign particles from the GI tract which probably lead to low bioavailability. Unlike the relatively high requirements of intravenous infusions, oral formulations could include high-molecular weight polymers as long as these components are metabolizable and cannot find their way into the systemic circulation. Hence, it may be an effective means of increasing uptake of drugs with mucoadhesive PMs [29, 30], and there have been considerable interests in the concept of mucoadhesive PMs.

5. Micelles with built-in drug-interactive domain as improved delivery systems

The drug-loading capacity of polymeric micelles is critically dependent on the compatibility between the drug and the micelle core [31]. A series of studies have demonstrated that
the drug-loading capacity of micelles can be greatly enhanced by optimizing chemical structures of the inner core segment for stronger drug/carrier interaction. A typical example of the strategy for enhanced compatibility between drug and block copolymer is the development of hydrotropic polymers. Hydrotropy refers to a phenomenon that the aqueous solubility of a poorly soluble compound is signifi cantly enhanced by the presence of large amounts of a second solute, named hydrotrope [32]. The hydrotropes aggregate only above a certain concentration, which is known as the minimal hydrotrope concentration (MHC) [33]. Various studies have been carried out to elucidate the process of hydro tropic solubilization. Although the exact mechanism is not fully clarified, it may involve multiple noncovalent interactions including hydrophobic interaction, hydrogen bonding [30] as well as parallel stacking effect [34, 35].

6. PEG-drug conjugates as dual-function carriers for cancer targeted delivery

PEG-Vitamin E Conjugates as Dual-Function Carriers for Cancer-Targeted Delivery D-α-tocopheryl polyethylene glycol (PEG) 1,000 succinate (TPGS) is a PEG-derivatized natural vitamin E which has been approved by FDA as a safe pharmaceutical adjuvant for drug formulation. In recent years, the application of TPGS in drug formulations has been extensively studied, such as emulsifier in poly (lactic-co-glycolic acid) (PLGA) nanoparticles, solubilizer and permeation enhancer [36], TPGS based liposomes [37], copolymers [38], and nanocrystal [39]. By inhibiting the function of P-glycoprotein (P-gp), TPGS also helps to overcome the multidrug resistance [40] and enhance the oral bioavailability of anticancer drugs [41]. In addition, TPGS-doxorubicin conjugate was developed as a prodrug for enhanced therapeutic effect [42].

7. PEG-derivatized Embelin as a nanocarrier

Bearing a long lipophilic chain, embelin is extremely hydrophobic and water-insoluble. In an attempt to explore the PEG modification as an approach to increase its water solubility, we have found that PEG-derivatized embelin forms micelles in aqueous solution [43]. This is not a surprise considering the structural similarity between embelin and vitamin E. Interestingly, the antitumor activity of embelin was well retained after coupling with PEG chain [43]. In addition, the PEG-embelin micelles are highly efficient in solubilizing various types of anticancer agent such as paclitaxel [43, 44]. Furthermore, PEG-embelin, at nanomolar range, showed synergistic effect with paclitaxel in several cancer cell lines tested [45].
8. Conclusion

Overall study revealed that the polymeric micelles have potential to be act as a targeted nanocarrier for delivery of various therapeutic agents. Hence polymeric micelles can be used for the drug delivery application.

References

1. Yifei Zhang, Yixian Huang, and Song Li. "Polymeric Micelles: Nanocarriers for Cancer-Targeted Drug Delivery". Journal of Drug Delivery & Therapeutics. 2020; 10(1):s191-195.
2. Gaurer G, Durcens MH, Satg KV, Nangy, and Maysinger D. "Block copolymer micelles: preparation, characterization and application in drug delivery." Journal of Control Release. 2005; 106(1-3):169–88.
3. Sutton D, Nasongkla N, Blanca E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res. 2007; 24(6):1029–46.
4. Rarokar, K. "Micelles as drug delivery depot system: an alternative approach for the controlled delivery of docetaxel." AAPS PharmaSciTech. 2005; 191, 436–445. DOI:10.1208/s12249-004-0376-y
5. Alakhov V, Y. Moskaleva E. Y, Batalova E. V, and A. V. Kabanov. "Hyperosmotic drug delivery: A concise review and update." Journal of Drug Delivery Science and Technology. 2009; 19(3):328–33.
6. Chung J, Y. Koyama M, Aoyagi T, Sakurai, Y, Okano T, et al. "Effect of coating on the morphology of diblock copolymers." J Controlled Release. 2007; 121(2):278–40.
7. Geng Y, Dalheimer P, Cai S, Tsai R, Tewari M, Minko T, et al. "Micelles self-assembled from poly(ethylene oxide)-block-poly(N-hexyl stearate-L-aspartamide) by a solvent evaporation method: effect on the solubilization and haemolytic activity of amphotericin B." Journal of Controlled Release. 2001; 77, no. 1-2, pp. 155–160, 2001. View at Publisher - View at Google Scholar - View at Scopus.
8. Jin, Q. "Thermosensitive polymer micelles as drug carriers." Journal of Drug Delivery & Therapeutics. 2020; 10(1):s191-195.
9. Kabanov V.A., Velotto D., L. Kherbeck, W. G. Pitt, A. Hubbell, and D. A. Christensen. "Investigating the acoustic release of doxorubicin from targeted micelles." Colloids and Surfaces B, vol. 101, pp. 153–155, 2013. View at Publisher - View at Google Scholar.
10. Liu G, X. Li, and S. Kwon. "Micelles self-assembled from poly(ethylene oxide)-block-poly(N-hexyl stearate-L-aspartamide) by a solvent evaporation method: effect on the solubilization and haemolytic activity of amphotericin B." Journal of Controlled Release. 2017; 7(6):1-6.
11. Rarokar, N.R., Khedekar P.B., Formulation and evaluation of docetaxel triblock loaded self-assembled nanocarriers for treatment of HER2 positive breast cancer. Journal of Drug delivery and Therapeutics. 2017; 7(6):1-6.
12. Jin, Q. "Thermosensitive polymer micelles as drug carriers." Journal of Drug Delivery & Therapeutics. 2020; 10(1):s191-195.
13. Rarokar, N.R., Khedekar P.B., Bharne A., Umekar M., Development of self-assembled nanocarriers to enhance antitumor efficacy of docetaxel trilactone in MDA-MB-231 cell line. Int. J. Biol. Macromol. 2012; 49(3):1056–1068. DOI:10.1016/j.ijbiomac.2012.02.130.
14. Choucair A, Eisenberg A. "Control of amphiphilic block copolymer morphologies using solution conditions." Eur Phys J E Soft Matter. 2003; 10(1):37–44.
15. Yu Y, Zhang L, Eisenberg A. "Morphogenic effect of solvent on the self-assembly of amphiphilic diblock copolymers." Macromolecules. 1998; 31(4):1144–54.
16. Shen H, Zhang L, Eisenberg A. "Multiple pH-induced morphological changes in aggregates of polystyrene-block-poly(4-vinylpyridine) in DMF/H2O mixtures." J Am Chem Soc. 1999; 121(12):2729–40.
17. Geng Y, Dalheimer P, Cai S, Tsai R, Tewari M, Minko T, et al. "Shape effects of filaments versus spherical particles in flow and drug delivery." Nat Nanotechnol. 2007; 2(4):249–55.
18. Benahmed A, Ranger M, Loroux J-C. "Novel polymeric micelles based on the amphiphilic diblock copolymer poly(4-vinyl-2-pyrrolidone)-block-poly(D,L-lactide)." Pharm Res. 2001; 18(3):328.
19. Yu Y, Zhang L, Eisenberg A. "Morphogenic effect of solvent on the self-assembly of amphiphilic diblock copolymers." Macromolecules. 1998; 31(4):1144–54.
20. Shen H, Zhang L, Eisenberg A. "Multiple pH-induced morphological changes in aggregates of polystyrene-block-poly(4-vinylpyridine) in DMF/H2O mixtures." J Am Chem Soc. 1999; 121(12):2729–40.
21. Geng Y, Dalheimer P, Cai S, Tsai R, Tewari M, Minko T, et al. "Shape effects of filaments versus spherical particles in flow and drug delivery." Nat Nanotechnol. 2007; 2(4):249–55.
22. Benahmed A, Ranger M, Loroux J-C. "Novel polymeric micelles based on the amphiphilic diblock copolymer poly(4-vinyl-2-pyrrolidone)-block-poly(D,L-lactide)." Pharm Res. 2001; 18(3):328.
23. Chung J, Y, Koyama M, Aoyagi T, Sakurai Y, Okano T. "Effect of molecular architecture of hydrophobically modified poly(N-isopropylacrylamide) on the formation of thermoresponsive core-shell micellar drug carriers." J Control Release. 1998; 53(1–3):311–30.
24. Riess G. "Micellization of block copolymers." Progress in Polymer Science. 2007, vol. 28, no. 7, pp. 1107–1170, 2003. View at Publisher - View at Google Scholar - View at Scopus.
25. Jones M-C. and J-C. Loroux, "Polymeric micelles—a new generation of coloidal drug carriers," European Journal of Pharmaceutics and Biopharmaceutics. vol. 48, no. 2, pp. 101–111, 1999. View at Publisher - View at Google Scholar - View at Scopus.
26. Rarokar N.R., Saooj S.D., Khedekar P.B., Investigation of effectiveness of some extensively used polymers on thermoresponsive properties of Pluronic® tri-block copolymers, J Drug Delivery Sci Technol. 44 (2018) 220–230. DOI:10.1016/j.jddst.2017.12.002.
27. Van Butsela K, Sibert P, Fustin C. A. et al., “Synthesis and pH-dependent micellization of diblock copolymer mixtures,” Journal of Colloid and Interface Science, vol. 329, no. 2, pp. 235–243, 2009. View at Publisher - View at Google Scholar - View at Scopus.
28. Parajapati SK, Maurya SD, Das MK, Tilak VK, Verma KK, Dhakar RC. Potential application of dendrimers in drug delivery: A concise review and update, Journal of Drug Delivery Science and Technology. 2009; 19(3):328–33.
29. Alakhov V, Y. Moskaleva E. Y, Batalova E. V, and A. V. Kabanov. "Hyperosmotic drug delivery: A concise review and update." Journal of Drug Delivery Science and Technology. 2009; 19(3):328–33.
30. Rarokar N.R., Saooj S.D., Khedekar P.B., Nanostructured cubosomes in a thermoresponsive depot system: an alternative approach for the controlled delivery of docetaxel. AAPS PharmSciTech 17 (2016) 436–445. DOI:10.1208/s12249-016-0396-y
31. Nishiyama N, Kataoka K. "Preparation and characterization of size-controlled polymeric micelle containing cis-dichlorodiammineplatinum(II) in the core," Journal of Controlled Release, vol. 74, no. 1-3, pp. 83–94, 2001. View at Publisher - View at Google Scholar - View at Scopus.
32. Yin Y, Zhang L, Eisenberg A. "Morphogenic effect of solvent on the self-assembly of amphiphilic diblock copolymer.
33. Shen H, Zhang L, Eisenberg A. "Multiple pH-induced morphological changes in aggregates of polystyrene-block-poly(4-vinylpyridine) in DMF/H2O mixtures." J Am Chem Soc. 1999; 121(12):2729–40.
34. Geng Y, Dalheimer P, Cai S, Tsai R, Tewari M, Minko T, et al. "Shape effects of filaments versus spherical particles in flow and drug delivery." Nat Nanotechnol. 2007; 2(4):249–55.
35. Benahmed A, Ranger M, Loroux J-C. "Novel polymeric micelles based on the amphiphilic diblock copolymer poly(4-vinyl-2-pyrrolidone)-block-poly(D,L-lactide)." Pharm Res. 2001; 18(3):328.
34. Kim JY, Kim S, Papp M, Park K, Pinal R. Hydrotropic solubilization of poorly water-soluble drugs. J Pharm Sci. 2010; 99(9):3953-65.
35. Cui Y. Parallel stacking of caffeine with riboflavin in aqueous solutions: the potential mechanism for hydrotropic solubilization of riboflavin. Int J Pharm. 2010; 397(1-2):36-43.
36. Ooya T, Lee S, Huh K, Park K. Hydrotropic nanocarriers for poorly soluble drugs. In: Mozafari MR, editor. Nanocarrier technologies. Netherlands: Springer; 2006. p. 51–73.
37. Yu L, Bridges A, Polli J, Vickers A, Long S, Roy A, et al. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res. 1999; 16(12):1812-7.
38. Muru MS, Kulkarni SA, Xiong J, Feng SS. Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int J Pharm. 2011; 421(2):332–40.
39. Zhang Z, Feng SS. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials. 2006; 27(2):262-70.
40. Liu Y, Huang L, Liu F. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Mol Pharm. 2010; 7(3):863-9.
41. Cheng X. Developing organic and inorganic nanomedicine for cancer therapy. Journal of Drug Delivery and Therapeutics. 2017; 7(2):1-4.
42. Varma MV, Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci. 2005; 25(4-5):445-53.
43. Cao N, Feng SS. Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials. 2008; 29(28):3856-65.
44. Huang Y, Lu J, Gao X, Li J, Zhao W, Sun M, et al. PEG derivatized embelin as a dual functional carrier for the delivery of paclitaxel. Bioconjug Chem. 2012; 23(7):1443-51.
45. Lu J, Huang Y, Zhao W, Marquez RT, Meng X, Li J, et al. PEG derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers. Biomaterials. 2013; 34(5):1591–600.